Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (129)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

  3. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

    The Lancet Microbe, Vol. 5, Núm. 6, pp. e559-e569

  4. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study

    Pediatrics, Vol. 153, Núm. 3

  5. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

    The Lancet, Vol. 404, Núm. 10454, pp. 773-786

  6. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

    The Lancet Respiratory Medicine, Vol. 12, Núm. 7, pp. 523-534

  7. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation

    Transplantation, Vol. 108, Núm. 9, pp. 1834-1866

2023

  1. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

    European Heart Journal, Vol. 44, Núm. 39, pp. 4043-4140

  2. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  3. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  4. Cerebral Oximetry Monitoring in Extremely Preterm Infants

    New England Journal of Medicine, Vol. 388, Núm. 16, pp. 1501-1511

  5. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib

    European urology, Vol. 83, Núm. 3, pp. 200-209

  6. Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013–2019)

    Antibiotics, Vol. 12, Núm. 11

  7. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

  8. Orthostatic Tremor

    Contemporary Clinical Neuroscience (Springer Nature), pp. 247-269

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  3. Acute onset movement disorders in diabetes mellitus: A clinical series of 59 patients

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2241-2248

  4. An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

    Pulmonary Circulation, Vol. 12, Núm. 1

  5. Association of chest compression pause duration prior to E-CPR cannulation with cardiac arrest survival outcomes

    Resuscitation, Vol. 177, pp. 85-92